Recensement national histologique des tumeurs primitives du système nerveux central : résultats généraux sur 40 000 cas, principales applications actuelles et perspectives

Zouaoui, Sonia; Rigau, Valérie; Mathieu-Daude, Hélène; Darlix, Amélie; Bessaoud, Faïza; Fabbro‐Peray, Pascale; Bauchet, Fabienne; Kerr, Christine; Fabbro, Michel; Figarella‐Branger, Dominique; Taillandier, Luc; Duffau, Hugues; Trétarre, Brigitte; Bauchet, Luc

doi:10.1016/j.neuchi.2012.01.004

Cited by 53 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The NF2 deletion may be associated with alterations in cells leading to the fibroblastic subtype of meningioma [ 5 ]. This is consistent with the underrepresentation of this subtype in canine meningioma compared to human meningioma [ 37 , 38 ]. Pavelin et al [ 39 ] also found lower levels of the NF2-associated merlin gene loss in meningothelial meningiomas compared to fibroblastic meningiomas.…”

Section: Discussionsupporting

confidence: 86%

RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma

et al. 2017

View full text Add to dashboard Cite

Meningiomas are the most commonly reported primary intracranial tumor in dogs and humans and between the two species there are similarities in histology and biologic behavior. Due to these similarities, dogs have been proposed as models for meningioma pathobiology. However, little is known about specific pathways and individual genes that are involved in the development and progression of canine meningioma. In addition, studies are lacking that utilize RNAseq to characterize gene expression in clinical cases of canine meningioma. The primary objective of this study was to develop a technique for which high quality RNA can be extracted from formalin-fixed, paraffin embedded tissue and then used for transcriptome analysis to determine patterns of gene expression. RNA was extracted from thirteen canine meningiomas–eleven from formalin fixed and two flash-frozen. These represented six grade I and seven grade II meningiomas based on the World Health Organization classification system for human meningioma. RNA was also extracted from fresh frozen leptomeninges from three control dogs for comparison. RNAseq libraries made from formalin fixed tissue were of sufficient quality to successfully identify 125 significantly differentially expressed genes, the majority of which were related to oncogenic processes. Twelve genes (AQP1, BMPER, FBLN2, FRZB, MEDAG, MYC, PAMR1, PDGFRL, PDPN, PECAM1, PERP, ZC2HC1C) were validated using qPCR. Among the differentially expressed genes were oncogenes, tumor suppressors, transcription factors, VEGF-related genes, and members of the WNT pathway. Our work demonstrates that RNA of sufficient quality can be extracted from FFPE canine meningioma samples to provide biologically relevant transcriptome analyses using a next-generation sequencing technique, such as RNA-seq.

show abstract

Section: Discussionsupporting

confidence: 86%

RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Its methodology has been previously published. 11,15 For this study, the FBTDB and the Club of Neuro-Oncology of the Société Française de Neurochirurgie were screened to identify cases of glioblastoma (GBM) with spinal location. Before inclusion, it was verified by 1 investigator (A.A. or 1 local neurosurgeon specialized in neuro-oncology) that all patients met the following inclusion criteria: (1) age 18 years or older at diagnosis, (2) spinal location, (3) histopathologic diagnosis of newly GBM according to the World Health Organization (WHO) classification, version 2016 (prevailing classification during the study), and (4) surgical management between January 1, 2004, and December 31, 2016.…”

Section: Methodsmentioning

confidence: 99%

Natural Course and Prognosis of Primary Spinal Glioblastoma

Amelot

Terrier²,

Mathon³

et al. 2023

Neurology

View full text Add to dashboard Cite

Background and Objectives.Primary spinal glioblastoma is extremely rare. The dramatic neurological deterioration and unresectability of primary spinal glioblastoma makes it a particularly disabling malignant neoplasm. Since it is a rare and heterogeneous disease, the assessment of prognostic factors remains limited.Methods.Primary spinal glioblastomas were identified from The French Brain Tumor Database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively. Inclusion criteria were age ≥ 18 years at diagnosis, spinal location, histopathological diagnosis of newly glioblastoma according to the 2016 World Health Organization classification, and surgical management between 2004 and 2016. Diagnosis was confirmed by a centralized neuropathological review. The primary outcome was overall survival. Therapeutic interventions and neurological outcomes were also collected.Results.Thirty-three patients with an histopathologically confirmed primary spinal glioblastoma (median age 50.9 years) were included (27 centers). The median overall survival (OS) was 13.1 months (range 2.5-23.7) and the median progression-free survival was 5.9 months (range 1.6-10.2). In multivariable analyses using Cox model, ECOG PS at 0-1 was the only independent predictor of longer OS [Hazard Ratio: 0.13, 95%CI 0.02-0.801; p=0.02], whereas a Karnofsky PS score <60 [Hazard Ratio: 2.89, 95%CI 1.05-7.92; p=0.03] and a cervical anatomical location [Hazard Ratio: 4.14, 95%CI 1.32-12.98; p=0.01] were independent predictors of shorter OS. The ambulatory status (Frankel D-E) [Hazard Ratio: 0.38, 95%CI 0.07-1.985; p=0.250] was not an independent prognostic factor while the concomitant standard radiochemotherapy with temozolomide (Stupp protocol) [Hazard Ratio: 0.35, 95%CI 0.118-1.05; p=0.06] was at the limit of significance.Discussion.Preoperative ECOG PS, Karnofsky PS score and the location are independent predictors of overall survival of primary spinal glioblastomas in adults. Further analyses are required to capture the survival benefit of concomitant standard radiochemotherapy with temozolomide.

show abstract

“…Primary cerebral lymphoma (PCL) is a rare form of non-Hodgkin lymphoma representing <5% of primary cerebral tumors ( 83 ). It may be associated with lymphomatous locations in the meninges (15–20%), the eye (10–20%) and the spinal cord (<5%) but is defined by the absence of any systemic lesion.…”

Section: Primary Cns Lymphomamentioning

confidence: 99%

Rare Primary Central Nervous System Tumors in Adults: An Overview

et al. 2020

View full text Add to dashboard Cite

Overall, tumors of primary central nervous system (CNS) are quite common in adults with an incidence rate close to 30 new cases/100,000 inhabitants per year. Significant clinical and biological advances have been accomplished in the most common adult primary CNS tumors (i.e., diffuse gliomas). However, most CNS tumor subtypes are rare with an incidence rate below the threshold defining rare disease of 6.0 new cases/100,000 inhabitants per year. Close to 150 entities of primary CNS tumors have now been identified by the novel integrated histomolecular classification published by the World Health Organization (WHO) and its updates by the c-IMPACT NOW consortium (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). While these entities can be better classified into smaller groups either by their histomolecular features and/or by their location, assessing their treatment by clinical trials and improving the survival of patients remain challenging. Despite these tumors are rare, research, and advances remain slower compared to diffuse gliomas for instance. In some cases (i.e., ependymoma, medulloblastoma) the understanding is high because single or few driver mutations have been defined. The European Union has launched European Reference Networks (ERNs) dedicated to support advances on the clinical side of rare diseases including rare cancers. The ERN for rare solid adult tumors is termed EURACAN. Within EURACAN, Domain 10 brings together the European patient advocacy groups (ePAGs) and physicians dedicated to improving outcomes in rare primary CNS tumors and also aims at supporting research, care and teaching in the field. In this review, we discuss the relevant biological and clinical characteristics, clinical management of patients, and research directions for the following types of rare primary CNS tumors: medulloblastoma, pineal region tumors, glioneuronal and rare glial tumors, ependymal tumors, grade III meningioma and mesenchymal tumors, primary central nervous system lymphoma, germ cell tumors, spinal cord tumors and rare pituitary tumors.

show abstract

Recensement national histologique des tumeurs primitives du système nerveux central : résultats généraux sur 40 000 cas, principales applications actuelles et perspectives

Cited by 53 publications

References 16 publications

RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma

RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma

Natural Course and Prognosis of Primary Spinal Glioblastoma

Rare Primary Central Nervous System Tumors in Adults: An Overview

Contact Info

Product

Resources

About